Gilead Sciences (NASDAQ:GILD) Receives “Neutral” Rating from Cantor Fitzgerald

Gilead Sciences (NASDAQ:GILD – Get Free Report)‘s stock had its “neutral” rating reaffirmed by equities researchers at Cantor Fitzgerald in a research note issued to investors on Friday, Benzinga reports. They currently have a $70.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target points to a potential downside of 4.97% from the […]

Leave a Reply

Your email address will not be published.

Previous post CF Industries (NYSE:CF) Price Target Increased to $83.00 by Analysts at Bank of America
Next post World Mobile Token (WMT) Hits Self Reported Market Cap of $119.23 Million